Frankfurt
12.01.26 | 08:48
0,006 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,008 | 0,009 | 13.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VERICI DX Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Verici Dx PLC - Completion of CAP accreditation audit | - | RNS | ||
| 06.11.25 | Verici Dx PLC - Provider Participation Agreement with Prime Health | - | RNS | ||
| 03.11.25 | TRADING UPDATES: Northcoders contract wins; Verici Dx completes audit | 1 | Alliance News | ||
| 03.11.25 | Verici Dx PLC - Completion of ISO 27001 surveillance audit | - | RNS | ||
| 30.10.25 | Verici Dx revises option pricing, grants new share options | 2 | Investing.com | ||
| 30.10.25 | Verici Dx PLC - Options revision & Grant of new share options | - | RNS | ||
| 06.10.25 | IN BRIEF: Verici Dx shares jump as posts progress on Tutivia adoption | 2 | Alliance News | ||
| 06.10.25 | Verici Dx PLC - Board Changes | - | RNS | ||
| 06.10.25 | Verici Dx PLC - Update on Tutivia test adoption | - | RNS | ||
| 30.09.25 | AIM WINNERS & LOSERS: Verici Dx rises; Billington profit plunges | 2 | Alliance News | ||
| 30.09.25 | Verici Dx PLC - Half-year Report | - | RNS | ||
| 31.07.25 | Verici Dx PLC - Tutivia abstracts for World Transplant Congress | - | RNS | ||
| 30.07.25 | Verici Dx shareholders approve all resolutions at annual meeting | 1 | Investing.com | ||
| 30.07.25 | Verici Dx: Aktionäre nehmen alle Beschlüsse auf jährlicher Hauptversammlung an | 3 | Investing.com Deutsch | ||
| 30.07.25 | Verici Dx PLC - Result of Annual General Meeting | - | RNS | ||
| 29.07.25 | Verici Dx PLC - Result of WRAP Retail Offer | - | RNS | ||
| 22.07.25 | Verici Dx PLC - WRAP Retail Offer for up to £500,000 | - | RNS | ||
| 21.07.25 | Verici Dx PLC - Result of Placing & Subscription | 1 | RNS | ||
| 21.07.25 | Verici Dx to raise up to £5m to accelerate diagnostics roll-out | 1 | Sharecast | ||
| 21.07.25 | Verici Dx PLC - Proposed Fundraising | 1 | RNS |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 280,83 | +1,85 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 77,92 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 20,140 | -2,09 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| BEAM THERAPEUTICS | 34,550 | +2,55 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| BIONTECH | 92,05 | 0,00 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| QIAGEN | 40,415 | -1,26 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,100 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,700 | -1,28 % | ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook | ||
| ALUMIS | 22,110 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,280 | +1,50 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 74,13 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,940 | -0,12 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,760 | -6,56 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| DYNE THERAPEUTICS | 17,040 | -2,41 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,75 | +2,90 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target |
VERICI DX PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,006 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VERICI DX PLC finden Sie auf Wallstreet Online.